548P - Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Thymoma and Thymic Cancer
Imaging, Diagnosis and Staging
|Presenter||Hae Su Kim|
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix177-ix178. 10.1093/annonc/mdw600|
H.S. Kim1, S.H. Moon2, T. Lim1, J.S. Ahn3, K. Park3, K. Lee2, M. Ahn3
We conducted this study to investigate the value of early metabolic responses assessed by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting prognosis and monitoring treatment response in patients with unresectable thymic epithelial tumors (TETs).
Study subjects were selected from the prospective dataset of a phase II clinical trial for cisplatin plus Cremorphor EL-free paclitaxel. A total of thirty patients with unresectable TETs who underwent baseline and early post treatment scan after two cycles of chemotherapy were enrolled (22 male; mean age 55.0 ± 15.0 years). Metabolic parameters including metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of the tumor lesions were measured.
Multivariate analysis using Cox proportional hazards regression model showed that percent decrease of MTV (HR = 0.995 by 1% decrease, P = 0.037) and TLG (HR = 0.996 by 1% decrease, P = 0.044) were significant predictors of progression-free survival (PFS). Receiver operating characteristic curve identified an 88.0% decrease in MTV and a 92.0% decrease in TLG as the optimal cut-off value for disease progression. Responders with ≥88% of ΔMTV and ≥92% of Δ TLG had significantly longer PFS than non-responders (P = 0.012, 0.026, respectively).
The percent decrease in MTV and TLG of tumor lesions measured by early post treatment FDG PET/CT significantly associated with disease progression in this study. Early metabolic response based on these volumetric parameters has the potential to monitor treatment response and predict prognosis in patients with unresectable TETs.
Clinical trial indentification
Legal entity responsible for the study
All authors have declared no conflicts of interest.